2022 Fiscal Year Final Research Report
Evaluation of DNA aptamer raised against advanced glycation end products on comprehensive prevention of aging-related disorders
| Project/Area Number |
20K06475
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 42040:Laboratory animal science-related
|
|---|
| Research Institution | Showa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
広村 宗範 昭和大学, 医学部, 講師 (00773186)
森 雄作 昭和大学, 医学部, 准教授 (90595919)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 終末糖化産物 / RAGE / 糖尿病 / アプタマー |
|---|
| Outline of Final Research Achievements |
Diabetes has been shown to be associated with decreased life and health life expectancy. Advanced glycation end products (AGEs) are formed through a non-enzymatic glycation reaction of proteins, the process of which can be accelerated by aging or diabetes. Many studies have revealed that AGEs are involved in the pathogenesis of diabetic complications. However, it remains unclear whether AGEs are associated with decreased life and health life expectancy in diabetes. Recently, we developed DNA aptamers that can inhibit toxic effects of AGEs through directly binding to AGEs or receptor for AGEs (RAGE). In this study, we administrated these aptamers to high fat-fed db/db mice, a model of obesity-induced diabetes with shortened life span. We found that, compared to control aptamer, RAGE inhibitory DNA aptamer prevented kidney damage and improved survival in this model.
|
| Free Research Field |
糖尿病
|
| Academic Significance and Societal Importance of the Research Achievements |
日本では、成人の6人に1人が糖尿病あるいはその予備軍であると報告されており、人口の高齢化によってこの割合はさらに増加していくと予想される。このため、糖尿病による寿命および健康寿命の短縮への対策は重要な問題である。DNAアプタマーは核酸医薬で、抗体医薬品に比べて安価で、大量に調整もできることから、次世代のバイオ医薬品として注目を集めている。DNAアプタマーを用いることで、これまでには不可能とされたAGEs-RAGE系の特異的な阻害を行うことが可能となった。本研究から、糖尿病における腎障害および寿命に対するRAGE阻害DNAアプタマーの有用性が示され、新たな治療法の開発につながると予想される。
|
